InfuSystem Holdings, Inc. (AMEX: INFU) Stock Competitors & Peer Comparison
See INFU's competitors and their performance on the AMEX and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for INFU and its AMEX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INFU | $12.24 | +0.49% | 246M | 29.73 | $0.41 | N/A |
| ABT | $108.33 | -0.42% | 187.4B | 20.79 | $5.21 | +2.28% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $94.17 | +1.15% | 120.5B | 17.03 | $5.53 | +3.02% |
| SYK | $303.13 | -1.58% | 116.2B | 22.64 | $13.39 | +1.14% |
| BSX | $47.80 | +1.81% | 71.1B | 15.42 | $3.10 | N/A |
| EW | $89.90 | +0.13% | 51.8B | 33.29 | $2.70 | N/A |
| DXCM | $87.90 | -2.02% | 33.2B | 34.47 | $2.55 | N/A |
| GEHC | $68.86 | -1.23% | 31.1B | 15.10 | $4.56 | +0.20% |
| PHG | $25.89 | -0.61% | 25.3B | 14.79 | $1.75 | +3.82% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
INFU vs ABT Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, ABT has a market cap of 187.4B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while ABT trades at $108.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas ABT's P/E ratio is 20.79. In terms of profitability, INFU's ROE is +0.15%, compared to ABT's ROE of +0.11%. Regarding short-term risk, INFU is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
INFU vs BSX-PA Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, INFU's ROE is +0.15%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, INFU is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BSX-PA's competition here
Medtronic plc (NYSE: MDT)
INFU vs MDT Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, MDT has a market cap of 120.5B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while MDT trades at $94.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas MDT's P/E ratio is 17.03. In terms of profitability, INFU's ROE is +0.15%, compared to MDT's ROE of +0.11%. Regarding short-term risk, INFU is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
INFU vs SYK Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, SYK has a market cap of 116.2B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while SYK trades at $303.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas SYK's P/E ratio is 22.64. In terms of profitability, INFU's ROE is +0.15%, compared to SYK's ROE of +0.16%. Regarding short-term risk, INFU is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
INFU vs BSX Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, BSX has a market cap of 71.1B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while BSX trades at $47.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas BSX's P/E ratio is 15.42. In terms of profitability, INFU's ROE is +0.15%, compared to BSX's ROE of +0.15%. Regarding short-term risk, INFU is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
INFU vs EW Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, EW has a market cap of 51.8B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while EW trades at $89.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas EW's P/E ratio is 33.29. In terms of profitability, INFU's ROE is +0.15%, compared to EW's ROE of +0.10%. Regarding short-term risk, INFU is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for INFU.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
INFU vs DXCM Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, DXCM has a market cap of 33.2B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while DXCM trades at $87.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas DXCM's P/E ratio is 34.47. In terms of profitability, INFU's ROE is +0.15%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, INFU is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for INFU.Check DXCM's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
INFU vs GEHC Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, GEHC has a market cap of 31.1B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while GEHC trades at $68.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas GEHC's P/E ratio is 15.10. In terms of profitability, INFU's ROE is +0.15%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, INFU is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for INFU.Check GEHC's competition here
Koninklijke Philips N.V. (NYSE: PHG)
INFU vs PHG Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, PHG has a market cap of 25.3B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while PHG trades at $25.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas PHG's P/E ratio is 14.79. In terms of profitability, INFU's ROE is +0.15%, compared to PHG's ROE of +0.10%. Regarding short-term risk, INFU is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for INFU.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
INFU vs ZBH Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, ZBH has a market cap of 19B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while ZBH trades at $98.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas ZBH's P/E ratio is 11.56. In terms of profitability, INFU's ROE is +0.15%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, INFU is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
INFU vs ABMD Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas ABMD's P/E ratio is 65.36. In terms of profitability, INFU's ROE is +0.15%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, INFU is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
INFU vs PEN Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while PEN trades at $322.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas PEN's P/E ratio is 84.16. In terms of profitability, INFU's ROE is +0.15%, compared to PEN's ROE of +0.11%. Regarding short-term risk, INFU is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
INFU vs SWAV Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas SWAV's P/E ratio is 78.76. In terms of profitability, INFU's ROE is +0.15%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, INFU is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
INFU vs SNN Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, SNN has a market cap of 12.1B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while SNN trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas SNN's P/E ratio is 13.58. In terms of profitability, INFU's ROE is +0.15%, compared to SNN's ROE of +0.12%. Regarding short-term risk, INFU is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
INFU vs ALGN Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, ALGN has a market cap of 11.4B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while ALGN trades at $158.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas ALGN's P/E ratio is 14.46. In terms of profitability, INFU's ROE is +0.15%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, INFU is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for INFU.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
INFU vs GMED Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, GMED has a market cap of 10.6B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while GMED trades at $78.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas GMED's P/E ratio is 17.63. In terms of profitability, INFU's ROE is +0.15%, compared to GMED's ROE of +0.12%. Regarding short-term risk, INFU is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for INFU.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
INFU vs GKOS Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, GKOS has a market cap of 10.5B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while GKOS trades at $177.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas GKOS's P/E ratio is -206.37. In terms of profitability, INFU's ROE is +0.15%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, INFU is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check GKOS's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
INFU vs BIO-B Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, BIO-B has a market cap of 10.4B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while BIO-B trades at $381.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas BIO-B's P/E ratio is -67.15. In terms of profitability, INFU's ROE is +0.15%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, INFU is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for INFU.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
INFU vs BIO Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, BIO has a market cap of 10.4B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while BIO trades at $386.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas BIO's P/E ratio is 41.65. In terms of profitability, INFU's ROE is +0.15%, compared to BIO's ROE of +0.03%. Regarding short-term risk, INFU is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BIO's competition here
Insulet Corp. (NASDAQ: PODD)
INFU vs PODD Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, PODD has a market cap of 10.2B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while PODD trades at $147.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas PODD's P/E ratio is 25.12. In terms of profitability, INFU's ROE is +0.15%, compared to PODD's ROE of +0.27%. Regarding short-term risk, INFU is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for INFU.Check PODD's competition here
Masimo Corporation (NASDAQ: MASI)
INFU vs MASI Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas MASI's P/E ratio is 44.43. In terms of profitability, INFU's ROE is +0.15%, compared to MASI's ROE of +0.09%. Regarding short-term risk, INFU is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for INFU.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
INFU vs BRKR Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, BRKR has a market cap of 8.9B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while BRKR trades at $58.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas BRKR's P/E ratio is 29.40. In terms of profitability, INFU's ROE is +0.15%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, INFU is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
INFU vs BRKRP Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, BRKRP has a market cap of 8.6B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while BRKRP trades at $431.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas BRKRP's P/E ratio is 234.13. In terms of profitability, INFU's ROE is +0.15%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, INFU is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for INFU.Check BRKRP's competition here
Inari Medical, Inc. (NASDAQ: NARI)
INFU vs NARI Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas NARI's P/E ratio is -59.24. In terms of profitability, INFU's ROE is +0.15%, compared to NARI's ROE of -0.00%. Regarding short-term risk, INFU is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for INFU.Check NARI's competition here
Haemonetics Corporation (NYSE: HAE)
INFU vs HAE Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, HAE has a market cap of 4.7B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while HAE trades at $102.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas HAE's P/E ratio is 20.54. In terms of profitability, INFU's ROE is +0.15%, compared to HAE's ROE of +0.11%. Regarding short-term risk, INFU is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for INFU.Check HAE's competition here
LivaNova PLC (NASDAQ: LIVN)
INFU vs LIVN Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, LIVN has a market cap of 4.5B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while LIVN trades at $81.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas LIVN's P/E ratio is 19.46. In terms of profitability, INFU's ROE is +0.15%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, INFU is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for INFU.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
INFU vs ITGR Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while ITGR trades at $126.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas ITGR's P/E ratio is 19.76. In terms of profitability, INFU's ROE is +0.15%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, INFU is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
INFU vs IRTC Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, IRTC has a market cap of 4.1B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while IRTC trades at $123.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas IRTC's P/E ratio is -287.05. In terms of profitability, INFU's ROE is +0.15%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, INFU is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for INFU.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
INFU vs AXNX Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas AXNX's P/E ratio is -709.80. In terms of profitability, INFU's ROE is +0.15%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, INFU is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for INFU.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
INFU vs TMDX Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while TMDX trades at $89.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas TMDX's P/E ratio is 45.68. In terms of profitability, INFU's ROE is +0.15%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, INFU is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
INFU vs AXGN Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, AXGN has a market cap of 2.6B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while AXGN trades at $48.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas AXGN's P/E ratio is 127.05. In terms of profitability, INFU's ROE is +0.15%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, INFU is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for INFU.Check AXGN's competition here
Neogen Corporation (NASDAQ: NEOG)
INFU vs NEOG Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while NEOG trades at $11.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas NEOG's P/E ratio is 42.25. In terms of profitability, INFU's ROE is +0.15%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, INFU is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for INFU.Check NEOG's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
INFU vs UFPT Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, UFPT has a market cap of 2.2B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while UFPT trades at $288.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas UFPT's P/E ratio is 29.50. In terms of profitability, INFU's ROE is +0.15%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, INFU is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for INFU.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
INFU vs ESTA Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while ESTA trades at $74.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas ESTA's P/E ratio is -58.96. In terms of profitability, INFU's ROE is +0.15%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, INFU is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for INFU.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
INFU vs NVCR Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while NVCR trades at $17.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas NVCR's P/E ratio is -13.80. In terms of profitability, INFU's ROE is +0.15%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, INFU is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for INFU.Check NVCR's competition here
NuVasive, Inc. (NASDAQ: NUVA)
INFU vs NUVA Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas NUVA's P/E ratio is 75.00. In terms of profitability, INFU's ROE is +0.15%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, INFU is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for INFU.Check NUVA's competition here
Butterfly Network, Inc. (NYSE: BFLY)
INFU vs BFLY Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, BFLY has a market cap of 2B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while BFLY trades at $7.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas BFLY's P/E ratio is -30.67. In terms of profitability, INFU's ROE is +0.15%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, INFU is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BFLY's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
INFU vs INSP Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while INSP trades at $63.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas INSP's P/E ratio is 27.76. In terms of profitability, INFU's ROE is +0.15%, compared to INSP's ROE of +0.18%. Regarding short-term risk, INFU is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for INFU.Check INSP's competition here
CONMED Corporation (NYSE: CNMD)
INFU vs CNMD Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while CNMD trades at $49.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas CNMD's P/E ratio is 10.84. In terms of profitability, INFU's ROE is +0.15%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, INFU is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for INFU.Check CNMD's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
INFU vs ATEC Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while ATEC trades at $9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas ATEC's P/E ratio is -157.50. In terms of profitability, INFU's ROE is +0.15%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, INFU is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for INFU.Check ATEC's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
INFU vs TNDM Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, TNDM has a market cap of 1.4B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while TNDM trades at $19.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas TNDM's P/E ratio is -21.40. In terms of profitability, INFU's ROE is +0.15%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, INFU is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for INFU.Check TNDM's competition here
Heska Corporation (NASDAQ: HSKA)
INFU vs HSKA Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas HSKA's P/E ratio is -62.49. In terms of profitability, INFU's ROE is +0.15%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, INFU is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for INFU.Check HSKA's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
INFU vs IART Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while IART trades at $16.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas IART's P/E ratio is 7.08. In terms of profitability, INFU's ROE is +0.15%, compared to IART's ROE of -0.01%. Regarding short-term risk, INFU is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for INFU.Check IART's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
INFU vs PRCT Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, PRCT has a market cap of 1.3B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while PRCT trades at $22.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas PRCT's P/E ratio is -11.73. In terms of profitability, INFU's ROE is +0.15%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, INFU is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check PRCT's competition here
Artivion, Inc. (NYSE: AORT)
INFU vs AORT Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while AORT trades at $25.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas AORT's P/E ratio is 42.63. In terms of profitability, INFU's ROE is +0.15%, compared to AORT's ROE of -0.01%. Regarding short-term risk, INFU is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for INFU.Check AORT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
INFU vs AVNS Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas AVNS's P/E ratio is 27.77. In terms of profitability, INFU's ROE is +0.15%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, INFU is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for INFU.Check AVNS's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
INFU vs LMRI Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, LMRI has a market cap of 1.2B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while LMRI trades at $12.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas LMRI's P/E ratio is -23.70. In terms of profitability, INFU's ROE is +0.15%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, INFU is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
INFU vs SILK Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas SILK's P/E ratio is -18.96. In terms of profitability, INFU's ROE is +0.15%, compared to SILK's ROE of -0.35%. Regarding short-term risk, INFU is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
INFU vs IRMD Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while IRMD trades at $83.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas IRMD's P/E ratio is 43.51. In terms of profitability, INFU's ROE is +0.15%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, INFU is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for INFU.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
INFU vs FNA Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas FNA's P/E ratio is -19.83. In terms of profitability, INFU's ROE is +0.15%, compared to FNA's ROE of -0.35%. Regarding short-term risk, INFU is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for INFU.Check FNA's competition here
Enovis Corporation (NYSE: ENOV)
INFU vs ENOV Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while ENOV trades at $18.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas ENOV's P/E ratio is 5.31. In terms of profitability, INFU's ROE is +0.15%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, INFU is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for INFU.Check ENOV's competition here
Bioventus Inc. (NASDAQ: BVS)
INFU vs BVS Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, BVS has a market cap of 953.2M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while BVS trades at $14.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas BVS's P/E ratio is 18.51. In terms of profitability, INFU's ROE is +0.15%, compared to BVS's ROE of +0.28%. Regarding short-term risk, INFU is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
INFU vs CBLL Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, CBLL has a market cap of 937.9M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while CBLL trades at $24.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas CBLL's P/E ratio is -14.05. In terms of profitability, INFU's ROE is +0.15%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, INFU is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CBLL's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
INFU vs AHCO Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, AHCO has a market cap of 883M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while AHCO trades at $6.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas AHCO's P/E ratio is 13.24. In terms of profitability, INFU's ROE is +0.15%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, INFU is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for INFU.Check AHCO's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
INFU vs AVR Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, AVR has a market cap of 879M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while AVR trades at $9.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas AVR's P/E ratio is -4.66. In terms of profitability, INFU's ROE is +0.15%, compared to AVR's ROE of -0.78%. Regarding short-term risk, INFU is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for INFU.Check AVR's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
INFU vs BBNX Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, BBNX has a market cap of 873.7M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while BBNX trades at $19.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas BBNX's P/E ratio is -11.77. In terms of profitability, INFU's ROE is +0.15%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, INFU is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BBNX's competition here
InMode Ltd. (NASDAQ: INMD)
INFU vs INMD Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, INMD has a market cap of 857M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while INMD trades at $14.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas INMD's P/E ratio is 10.35. In terms of profitability, INFU's ROE is +0.15%, compared to INMD's ROE of +0.12%. Regarding short-term risk, INFU is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for INFU.Check INMD's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
INFU vs CSII Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas CSII's P/E ratio is -20.83. In terms of profitability, INFU's ROE is +0.15%, compared to CSII's ROE of -0.14%. Regarding short-term risk, INFU is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for INFU.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
INFU vs SIBN Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, SIBN has a market cap of 820.5M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while SIBN trades at $18.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas SIBN's P/E ratio is -54.41. In terms of profitability, INFU's ROE is +0.15%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, INFU is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for INFU.Check SIBN's competition here
Varex Imaging Corporation (NASDAQ: VREX)
INFU vs VREX Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, VREX has a market cap of 779.3M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while VREX trades at $18.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas VREX's P/E ratio is 19.48. In terms of profitability, INFU's ROE is +0.15%, compared to VREX's ROE of +0.05%. Regarding short-term risk, INFU is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for INFU.Check VREX's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
INFU vs SSII Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, SSII has a market cap of 682.4M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while SSII trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas SSII's P/E ratio is -66.51. In terms of profitability, INFU's ROE is +0.15%, compared to SSII's ROE of -0.27%. Regarding short-term risk, INFU is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for INFU.Check SSII's competition here
Surmodics, Inc. (NASDAQ: SRDX)
INFU vs SRDX Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas SRDX's P/E ratio is -34.66. In terms of profitability, INFU's ROE is +0.15%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, INFU is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SRDX's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
INFU vs CTKB Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, CTKB has a market cap of 607M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while CTKB trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas CTKB's P/E ratio is -24.90. In terms of profitability, INFU's ROE is +0.15%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, INFU is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CTKB's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
INFU vs APEN Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas APEN's P/E ratio is -9.43. In terms of profitability, INFU's ROE is +0.15%, compared to APEN's ROE of -0.85%. Regarding short-term risk, INFU is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check APEN's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
INFU vs KIDS Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, KIDS has a market cap of 575.6M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while KIDS trades at $22.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas KIDS's P/E ratio is -18.99. In terms of profitability, INFU's ROE is +0.15%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, INFU is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check KIDS's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
INFU vs DCTH Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, DCTH has a market cap of 568.9M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while DCTH trades at $16.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas DCTH's P/E ratio is 1648.00. In terms of profitability, INFU's ROE is +0.15%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, INFU is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for INFU.Check DCTH's competition here
ZimVie Inc. (NASDAQ: ZIMV)
INFU vs ZIMV Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, INFU's ROE is +0.15%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, INFU is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ZIMV's competition here
Cerus Corporation (NASDAQ: CERS)
INFU vs CERS Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, CERS has a market cap of 521.9M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while CERS trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas CERS's P/E ratio is -51.70. In terms of profitability, INFU's ROE is +0.15%, compared to CERS's ROE of -0.10%. Regarding short-term risk, INFU is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
INFU vs NPCE Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, NPCE has a market cap of 508M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while NPCE trades at $14.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas NPCE's P/E ratio is -26.14. In terms of profitability, INFU's ROE is +0.15%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, INFU is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for INFU.Check NPCE's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
INFU vs TCMD Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, TCMD has a market cap of 493.3M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while TCMD trades at $21.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas TCMD's P/E ratio is 20.25. In terms of profitability, INFU's ROE is +0.15%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, INFU is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for INFU.Check TCMD's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
INFU vs SGHT Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, SGHT has a market cap of 454.3M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while SGHT trades at $8.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas SGHT's P/E ratio is -14.91. In terms of profitability, INFU's ROE is +0.15%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, INFU is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check SGHT's competition here
Carlsmed, Inc. (NASDAQ: CARL)
INFU vs CARL Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, CARL has a market cap of 424.1M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while CARL trades at $15.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas CARL's P/E ratio is -10.91. In terms of profitability, INFU's ROE is +0.15%, compared to CARL's ROE of -0.38%. Regarding short-term risk, INFU is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CARL's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
INFU vs PACB Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, PACB has a market cap of 419.3M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while PACB trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas PACB's P/E ratio is -3.29. In terms of profitability, INFU's ROE is +0.15%, compared to PACB's ROE of -49.62%. Regarding short-term risk, INFU is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for INFU.Check PACB's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
INFU vs CLPT Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, CLPT has a market cap of 418.7M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while CLPT trades at $13.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas CLPT's P/E ratio is -11.83. In terms of profitability, INFU's ROE is +0.15%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, INFU is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CLPT's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
INFU vs SENS Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, SENS has a market cap of 402.5M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while SENS trades at $9.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas SENS's P/E ratio is -4.32. In terms of profitability, INFU's ROE is +0.15%, compared to SENS's ROE of -1.66%. Regarding short-term risk, INFU is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
INFU vs OFIX Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, OFIX has a market cap of 375.5M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while OFIX trades at $9.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas OFIX's P/E ratio is -6.05. In terms of profitability, INFU's ROE is +0.15%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, INFU is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check OFIX's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
INFU vs CATX Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, CATX has a market cap of 358.1M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while CATX trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas CATX's P/E ratio is -2.36. In terms of profitability, INFU's ROE is +0.15%, compared to CATX's ROE of -0.42%. Regarding short-term risk, INFU is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CATX's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
INFU vs TMCI Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, TMCI has a market cap of 312M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while TMCI trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas TMCI's P/E ratio is -5.12. In terms of profitability, INFU's ROE is +0.15%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, INFU is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check TMCI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
INFU vs SMLR Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas SMLR's P/E ratio is 3.92. In terms of profitability, INFU's ROE is +0.15%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, INFU is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SMLR's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
INFU vs TLSI Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, TLSI has a market cap of 307.9M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while TLSI trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas TLSI's P/E ratio is -2.98. In terms of profitability, INFU's ROE is +0.15%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, INFU is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check TLSI's competition here
CapsoVision, Inc. (NASDAQ: CV)
INFU vs CV Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, CV has a market cap of 299.3M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while CV trades at $5.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas CV's P/E ratio is -2.40. In terms of profitability, INFU's ROE is +0.15%, compared to CV's ROE of -1.78%. Regarding short-term risk, INFU is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CV's competition here
Avita Medical Inc. (NASDAQ: RCEL)
INFU vs RCEL Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, RCEL has a market cap of 278.2M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while RCEL trades at $11.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas RCEL's P/E ratio is -7.78. In terms of profitability, INFU's ROE is +0.15%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, INFU is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for INFU.Check RCEL's competition here
RxSight, Inc. (NASDAQ: RXST)
INFU vs RXST Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, RXST has a market cap of 263.9M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while RXST trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas RXST's P/E ratio is -5.64. In terms of profitability, INFU's ROE is +0.15%, compared to RXST's ROE of -0.17%. Regarding short-term risk, INFU is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for INFU.Check RXST's competition here
Profound Medical Corp. (NASDAQ: PROF)
INFU vs PROF Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, PROF has a market cap of 250.4M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while PROF trades at $6.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas PROF's P/E ratio is -7.03. In terms of profitability, INFU's ROE is +0.15%, compared to PROF's ROE of -0.56%. Regarding short-term risk, INFU is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for INFU.Check PROF's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
INFU vs MGRM Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas MGRM's P/E ratio is -12.00. In terms of profitability, INFU's ROE is +0.15%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, INFU is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for INFU.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
INFU vs ELMD Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, ELMD has a market cap of 232.1M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while ELMD trades at $28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas ELMD's P/E ratio is 21.40. In terms of profitability, INFU's ROE is +0.15%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, INFU is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for INFU.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
INFU vs NVRO Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas NVRO's P/E ratio is -1.91. In terms of profitability, INFU's ROE is +0.15%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, INFU is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for INFU.Check NVRO's competition here
Neuronetics, Inc. (NASDAQ: STIM)
INFU vs STIM Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, STIM has a market cap of 200.4M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while STIM trades at $2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas STIM's P/E ratio is -6.55. In terms of profitability, INFU's ROE is +0.15%, compared to STIM's ROE of -1.51%. Regarding short-term risk, INFU is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for INFU.Check STIM's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
INFU vs BSGM Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas BSGM's P/E ratio is -5.81. In terms of profitability, INFU's ROE is +0.15%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, INFU is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BSGM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
INFU vs LUCD Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, LUCD has a market cap of 179.2M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while LUCD trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas LUCD's P/E ratio is -2.54. In terms of profitability, INFU's ROE is +0.15%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, INFU is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for INFU.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
INFU vs MDGS Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas MDGS's P/E ratio is -0.27. In terms of profitability, INFU's ROE is +0.15%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, INFU is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
INFU vs QIPT Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas QIPT's P/E ratio is -15.87. In terms of profitability, INFU's ROE is +0.15%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, INFU is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for INFU.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
INFU vs FOCL Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, FOCL has a market cap of 155.6M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while FOCL trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas FOCL's P/E ratio is -4.01. In terms of profitability, INFU's ROE is +0.15%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, INFU is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for INFU.Check FOCL's competition here
Quantum-Si incorporated (NASDAQ: QSI)
INFU vs QSI Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, QSI has a market cap of 151.5M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while QSI trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas QSI's P/E ratio is -1.67. In terms of profitability, INFU's ROE is +0.15%, compared to QSI's ROE of -0.47%. Regarding short-term risk, INFU is more volatile compared to QSI. This indicates higher risk in terms of short-term price fluctuations for INFU.Check QSI's competition here
Inogen, Inc. (NASDAQ: INGN)
INFU vs INGN Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, INGN has a market cap of 146.7M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while INGN trades at $5.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas INGN's P/E ratio is -5.96. In terms of profitability, INFU's ROE is +0.15%, compared to INGN's ROE of -0.13%. Regarding short-term risk, INFU is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
INFU vs QTRX Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, QTRX has a market cap of 126.7M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while QTRX trades at $2.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas QTRX's P/E ratio is -1.06. In terms of profitability, INFU's ROE is +0.15%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, INFU is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check QTRX's competition here
iCAD, Inc. (NASDAQ: ICAD)
INFU vs ICAD Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas ICAD's P/E ratio is -20.37. In terms of profitability, INFU's ROE is +0.15%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, INFU is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ICAD's competition here
LENSAR Inc (NASDAQ: LNSR)
INFU vs LNSR Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, LNSR has a market cap of 105.4M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while LNSR trades at $8.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas LNSR's P/E ratio is 8.76. In terms of profitability, INFU's ROE is +0.15%, compared to LNSR's ROE of +103.80%. Regarding short-term risk, INFU is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for INFU.Check LNSR's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
INFU vs HJLI Comparison September 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 246M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, INFU is priced at $12.24 on the AMEX, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 29.73, whereas HJLI's P/E ratio is N/A. In terms of profitability, INFU's ROE is +0.15%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, INFU is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check HJLI's competition here